Compare Stocks: ABEO, TRAX, REPL, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.03 +0.4%	$6.02	$4.00 ▼ $7.65	$287.62M	1.31	1.28 million shs	1.21 million shs
IMTX Immatics	$7.59 -10.1%	$9.07	$7.40 ▼ $12.41	$1.04B	1.36	505,023 shs	1.26 million shs
REPL Replimune Group	$13.07 -2.8%	$13.19	$1.50 ▼ $16.33	$1.23B	0.93	4.53 million shs	1.30 million shs
TRAX First Tracks Biotherapeutics	$33.28 -1.9%	$41.52	$14.72 ▼ $49.91	$1.19B	N/A	652,263 shs	1.17 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.57%	-7.73%	-16.22%	-21.72%	-5.11%
IMTX Immatics	-3.87%	+1.32%	-10.50%	-15.18%	-6.22%
REPL Replimune Group	+1.59%	+6.75%	-14.17%	+16.15%	+219.48%
TRAX First Tracks Biotherapeutics	-4.29%	-5.33%	-17.61%	+75.75%	+3,391,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.03 +0.4%	$6.02	$4.00 ▼ $7.65	$287.62M	1.31	1.28 million shs	1.21 million shs
IMTX Immatics	$7.59 -10.1%	$9.07	$7.40 ▼ $12.41	$1.04B	1.36	505,023 shs	1.26 million shs
REPL Replimune Group	$13.07 -2.8%	$13.19	$1.50 ▼ $16.33	$1.23B	0.93	4.53 million shs	1.30 million shs
TRAX First Tracks Biotherapeutics	$33.28 -1.9%	$41.52	$14.72 ▼ $49.91	$1.19B	N/A	652,263 shs	1.17 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.57%	-7.73%	-16.22%	-21.72%	-5.11%
IMTX Immatics	-3.87%	+1.32%	-10.50%	-15.18%	-6.22%
REPL Replimune Group	+1.59%	+6.75%	-14.17%	+16.15%	+219.48%
TRAX First Tracks Biotherapeutics	-4.29%	-5.33%	-17.61%	+75.75%	+3,391,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.67	Moderate Buy	$21.00	317.50% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	171.41% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-8.19% Downside
TRAX First Tracks Biotherapeutics	2.79	Moderate Buy	$65.17	95.81% Upside

Current Analyst Ratings Breakdown

Latest ABEO, TRAX, REPL, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	TRAX First Tracks Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/25/2026	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	ABEO Abeona Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/18/2026	ABEO Abeona Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $30.00
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
9/16/2026	TRAX First Tracks Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	49.42	N/A	N/A	$2.94 per share	1.71
IMTX Immatics	$54.60M	19.00	N/A	N/A	$4.09 per share	1.86
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)
TRAX First Tracks Biotherapeutics	N/A	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ABEO, TRAX, REPL, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/12/2026	Q2 2026	TRAX First Tracks Biotherapeutics	-$0.74	-$0.95	-$0.21	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
IMTX Immatics	N/A	7.54	7.54
REPL Replimune Group	1.00	5.23	5.23
TRAX First Tracks Biotherapeutics	N/A	14.28	14.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
IMTX Immatics	64.41%
REPL Replimune Group	92.53%
TRAX First Tracks Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
IMTX Immatics	3.30%
REPL Replimune Group	5.40%
TRAX First Tracks Biotherapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
REPL Replimune Group	465	93.80 million	88.73 million	Optionable
TRAX First Tracks Biotherapeutics	104	35.73 million	N/A	N/A

ABEO, TRAX, REPL, and IMTX Headlines

Recent News About These Companies

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Picked Up by Analysts at Canaccord Genuity Group

October 2 at 1:48 AM | americanbankingnews.com

Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a buy rating

October 1 at 7:28 AM | msn.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rated "Buy" in New Coverage at Canaccord Genuity Group

September 30 at 8:11 AM | marketbeat.com

30,339 Shares in First Tracks Biotherapeutics $TRAX Bought by Corient Private Wealth LP

September 30 at 3:04 AM | marketbeat.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Average Target Price of $66.55 According to Analysts

September 30 at 1:58 AM | americanbankingnews.com

Der aktuelle Kurs der First Tracks Biotherapeutics Inc Aktie beträgt 34,42.

September 26, 2026 | de.investing.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Consensus Target Price of $66.55 According to Analysts

September 25, 2026 | marketbeat.com

State Street Corp Buys 1,512,896 Shares of First Tracks Biotherapeutics $TRAX

September 25, 2026 | marketbeat.com

Tidal Investments LLC Makes New Investment in First Tracks Biotherapeutics $TRAX

September 22, 2026 | marketbeat.com

Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform

September 18, 2026 | streetinsider.com

Guggenheim initiates coverage of First Tracks Biotherapeutics with buy

September 17, 2026 | msn.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rating Upgraded by Guggenheim

September 17, 2026 | marketbeat.com

Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,

September 16, 2026 | streetinsider.com

Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Up 5.01%

September 14, 2026 | aaii.comA

Wellington Management Group LLP Makes New $1.16 Million Investment in First Tracks Biotherapeutics $TRAX

September 12, 2026 | marketbeat.com

Opaleye Management Inc. Invests $1.31 Million in First Tracks Biotherapeutics $TRAX

September 11, 2026 | marketbeat.com

J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock

September 5, 2026 | insidertrades.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock

September 4, 2026 | marketbeat.com

First Tracks Biotherapeutics' (TRAX) Buy Rating Reiterated at HC Wainwright

September 3, 2026 | marketbeat.com

First Tracks Biotherapeutics Inc (TRAX)

August 30, 2026 | de.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, TRAX, REPL, and IMTX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.03 +0.02 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$5.09 +0.06 (+1.19%)

As of 07:57 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Immatics NASDAQ:IMTX

$7.59 -0.85 (-10.07%)

Closing price 04:00 PM Eastern

Extended Trading

$7.59 0.00 (0.00%)

As of 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Replimune Group NASDAQ:REPL

$13.07 -0.38 (-2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$13.14 +0.07 (+0.57%)

As of 07:54 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

First Tracks Biotherapeutics NASDAQ:TRAX

$33.28 -0.64 (-1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$33.31 +0.03 (+0.09%)

As of 07:30 PM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, TRAX, REPL, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, TRAX, REPL, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, TRAX, REPL, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, TRAX, REPL, and IMTX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Immatics NASDAQ:IMTX

Replimune Group NASDAQ:REPL

First Tracks Biotherapeutics NASDAQ:TRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, TRAX, REPL, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, TRAX, REPL, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, TRAX, REPL, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, TRAX, REPL, and IMTX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Immatics NASDAQ:IMTX

Replimune Group NASDAQ:REPL

First Tracks Biotherapeutics NASDAQ:TRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools